The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 4
  • 1
    Fox, John Stephen, Dr
    Director born in August 1954
    Individual (5 offsprings)
    Officer
    2017-01-01 ~ now
    OF - director → CIF 0
  • 2
    Thurston, David Edwin, Professor
    Professor Of Drug Discovery born in May 1955
    Individual (6 offsprings)
    Officer
    2013-03-25 ~ now
    OF - director → CIF 0
  • 3
    Keightley, Christopher Alan, Dr
    Biochemist born in May 1954
    Individual (4 offsprings)
    Officer
    2013-05-29 ~ now
    OF - director → CIF 0
  • 4
    Dr Savvas Ioannou Neophytou
    Born in May 1972
    Individual (12 offsprings)
    Person with significant control
    2016-04-06 ~ now
    PE - Has significant influence or controlCIF 0
Ceased 2
  • 1
    Turner, Richard John
    Businessman born in June 1955
    Individual (31 offsprings)
    Officer
    2013-06-29 ~ 2017-06-15
    OF - director → CIF 0
  • 2
    Neophytou, Savvas Ioannou, Dr
    Director born in May 1972
    Individual (12 offsprings)
    Officer
    2016-03-31 ~ 2022-11-07
    OF - director → CIF 0
parent relation
Company in focus

TRANSCRIPTOGEN LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
02023-01-01 ~ 2023-12-31
02021-08-01 ~ 2022-12-31
Par Value of Share
Class 1 ordinary share
02023-01-01 ~ 2023-12-31
Debtors
13,997 GBP2023-12-31
812 GBP2022-12-31
Cash at bank and in hand
112,270 GBP2023-12-31
157,529 GBP2022-12-31
Current Assets
126,267 GBP2023-12-31
158,341 GBP2022-12-31
Creditors
Current
15,648 GBP2023-12-31
1,730 GBP2022-12-31
Net Current Assets/Liabilities
110,619 GBP2023-12-31
156,611 GBP2022-12-31
Total Assets Less Current Liabilities
110,619 GBP2023-12-31
156,611 GBP2022-12-31
Equity
Called up share capital
204 GBP2023-12-31
204 GBP2022-12-31
Share premium
472,562 GBP2023-12-31
472,562 GBP2022-12-31
Retained earnings (accumulated losses)
-362,147 GBP2023-12-31
-316,155 GBP2022-12-31
Equity
110,619 GBP2023-12-31
156,611 GBP2022-12-31
Other Debtors
Current, Amounts falling due within one year
13,997 GBP2023-12-31
812 GBP2022-12-31
Trade Creditors/Trade Payables
Current
14,063 GBP2023-12-31
Other Creditors
Current
1,585 GBP2023-12-31
1,730 GBP2022-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
20,327 shares2023-12-31

  • TRANSCRIPTOGEN LTD
    Info
    Registered number 08461104
    Unit 1, Cambridge House Camboro Business Park, Oakington Road, Girton, Cambridge, Cambridgeshire CB3 0QH
    Private Limited Company incorporated on 2013-03-25 (12 years 2 months). The company status is Active.
    The last date of confirmation statement was made at 2025-04-05
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.